INITIAL IMPROVEMENT AS PREDICTOR OF OUTCOME OF NEUROLEPTIC TREATMENTNEDOPIL N; RUETHER E.1981; PHARMACOPSYCHIATRIA; ISSN 0720-4280; DEU; DA. 1981; VOL. 14; NO 6; PP. 205-207; ABS. GER; BIBL. 13 REF.Article

ZUR SYMPTOMATOLOGIE DES NARKOLEPTISCHEN SYNDROMS = SYMPTOMATOLOGIE DU SYNDROME NARCOLEPTIQUERUETHER E; MEIER EWERT K; GALLITZ A et al.1972; NERVENARZT; DTSCH.; DA. 1972; VOL. 43; NO 12; PP. 640-643; BIBL. 19REF.Article

ZUR ZENTRALEN WIRKUNG VON BETA-REZEPTOREN BLOCKERN: SOTALOL = L'ACTION CENTRALE DES BETA BLOQUANTS: SOTALOLBENDER W; GREIL W; RUETHER E et al.1979; MED. WELT; DEU; DA. 1979; VOL. 31; NO 2; PP. 73-76; BIBL. 1 P.Article

ACUTE EFFECTS OF THE SYNTHETIC ANALOGUE OF METHIONINE ENKEPHALIN FK 33-824 ON DEPRESSIVE SYMPTOMSJUNGKUNZ G; NEDOPIL N; RUETHER E et al.1983; PHARMACOPSYCHIATRIA; ISSN 0720-4280; DEU; DA. 1983; VOL. 16; NO 3; PP. 90-92; ABS. GER; BIBL. 12 REF.Article

DREI NARKOLEPTISCHE SYNDROME. KATAMNESTISCHE UND POLYGRAPHISCHE ERGEBNISSE = TROIS SYNDROMES NARCOLEPTIQUES. RESULTATS CATAMNESTIQUES ET POLYGRAPHIQUESMEIER EWERT K; SCHOEPFER B; RUETHER E et al.1975; NERVENARZT; DTSCH.; DA. 1975; VOL. 46; NO 11; PP. 624-635; BIBL. DISSEM.Article

EFFECTS OF THE BETA-ADRENOCEPTOR BLOCKING AGENT SOTALOL ON CNS: SLEEP, EEG AND PSYCHOPHYSIOLOGICAL PARAMETERSBENDER W; GREIL W; RUETHER E et al.1979; J. CLIN. PHARMACOL.; USA; DA. 1979; VOL. 19; NO 8-9 PART. 2; PP. 505-512; BIBL. 20 REF.Article

The influence of intravenous L-tryptophan on plasma melatonin and sleep in menHAJAK, G; HUETHER, G; BLANKE, J et al.Pharmacopsychiatry. 1991, Vol 24, Num 1, pp 17-20, issn 0176-3679, 4 p.Article

ANTIPSYCHOTIC EFFECTS, SIDE EFFECTS AND EFFECTIVE DOSIS OF THE BUTYROPHENONE LENPERONE (AHR 2277).WOGGON B; FRANKE A; HUCKER H et al.1977; INTERNATION. PHARMACOPSYCHIATRY; SWITZ.; DA. 1977; VOL. 12; NO 2; PP. 113-126; BIBL. 14 REF.Article

GROWTH HORMONE RELEASE DURING SLEEP AND WITH THERMAL STIMULATION IN DEPRESSED PATIENTS. = DECHARGE D'HORMONE DE CROISSANCE PENDANT LE SOMMEIL ET AU COURS DE STIMULATION THERMIQUE CHEZ DES PATIENTS DEPRESSIFSSCHILKRUT R; CHADRA O; OSSWALD M et al.1975; NEUROPSYCHOBIOLOGY; SWITZ.; DA. 1975; VOL. 1; NO 2; PP. 70-79; BIBL. 1 P. 1/2Article

THE EFFECT OF L-5-HYDROXYTRYPTOPHAN ALONE AND IN COMBINATION WITH A DECARBOXYLASE INHIBITOR (RO 4-4602) IN DEPRESSIVE PATIENTSMATUSSEK N; ANGST J; BENKERT O et al.1974; ADV. BIOCHEM. PSYCHOPHARMACOL.; U.S.A.; DA. 1974; VOL. 11; PP. 399-404; BIBL. 13REF.Article

Psychoendocrine sequelae of chronic testosterone deficiencyEHRENREICH, H; HALARIS, A; RUETHER, E et al.Journal of psychiatric research. 1999, Vol 33, Num 5, pp 379-387, issn 0022-3956Article

CLINICAL PROFILE AND SERUM CONCENTRATION OF VILOXAZINE AS COMPARED TO AMITRIPTYLINEMUELLER OERLINGHAUSEN B; RUETHER E; ADAM HK et al.1979; PHARMAKOPSYCHIATR. NEURO-PSYCHOPHARMAKOL.; DEU; DA. 1979; VOL. 12; NO 4; PP. 321-337; ABS. GER; BIBL. 42 REF.Article

A 28-week, double-blind, placebo-controlled study with cerebrolysin in patients with mild to moderate Alzheimer's diseaseRUETHER, E; HUSMANN, R; KOPER, D et al.International clinical psychopharmacology. 2001, Vol 16, Num 5, pp 253-263, issn 0268-1315Article